SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will participate in the 24th Annual JPMorgan Healthcare Conference on January 9, 2006, at 8:30 a.m. (PST). Ted W. Love, MD, Nuvelo’s chairman and CEO, will provide a corporate overview and an update on the company’s plans for 2006.
A live audio webcast of the presentation will be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com or at http://equityconferences.jpmorgan.com .
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s clinical pipeline includes alfimeprase, a direct-acting thrombolytic in Phase 3 trials for the treatment of thrombotic-related disorders, and rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor complex that is currently in Phase 2 clinical development for acute coronary syndromes. Nuvelo is also progressing its preclinical development candidate, NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis. Nuvelo expects to leverage its expertise in secreted proteins and antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR of Nuvelo, +1-650-517-8472, or nestrin@nuvelo.com
